GB0317663D0 - Pharmaceutical composition - Google Patents
Pharmaceutical compositionInfo
- Publication number
- GB0317663D0 GB0317663D0 GBGB0317663.3A GB0317663A GB0317663D0 GB 0317663 D0 GB0317663 D0 GB 0317663D0 GB 0317663 A GB0317663 A GB 0317663A GB 0317663 D0 GB0317663 D0 GB 0317663D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0317663.3A GB0317663D0 (en) | 2003-07-29 | 2003-07-29 | Pharmaceutical composition |
| PCT/GB2004/003241 WO2005011647A2 (en) | 2003-07-29 | 2004-07-27 | Pharmaceutical composition |
| US10/565,100 US20070141141A1 (en) | 2003-07-29 | 2004-07-27 | Pharmaceutical composition |
| EP04743569A EP1651233A2 (en) | 2003-07-29 | 2004-07-27 | Pharmaceutical composition |
| JP2006521656A JP2007500176A (ja) | 2003-07-29 | 2004-07-27 | 医薬組成物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0317663.3A GB0317663D0 (en) | 2003-07-29 | 2003-07-29 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB0317663D0 true GB0317663D0 (en) | 2003-09-03 |
Family
ID=27799353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB0317663.3A Ceased GB0317663D0 (en) | 2003-07-29 | 2003-07-29 | Pharmaceutical composition |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20070141141A1 (https=) |
| EP (1) | EP1651233A2 (https=) |
| JP (1) | JP2007500176A (https=) |
| GB (1) | GB0317663D0 (https=) |
| WO (1) | WO2005011647A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007316558A1 (en) * | 2006-11-09 | 2008-05-15 | Abbott Gmbh & Co. Kg | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| EP1920767A1 (en) * | 2006-11-09 | 2008-05-14 | Abbott GmbH & Co. KG | Melt-processed imatinib dosage form |
| WO2009100176A2 (en) * | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| US8133506B2 (en) * | 2008-03-12 | 2012-03-13 | Aptalis Pharmatech, Inc. | Drug delivery systems comprising weakly basic drugs and organic acids |
| JP5382334B2 (ja) * | 2008-09-19 | 2014-01-08 | ブラザー工業株式会社 | インクジェット記録用水性インクおよび水性インクセット |
| JP5815554B2 (ja) * | 2009-12-16 | 2015-11-17 | ダウ グローバル テクノロジーズ エルエルシー | メチルセルロースをspfおよび/またはppdの上昇剤として組入れるサンスクリーン組成物ならびに方法 |
| JP4574742B1 (ja) * | 2010-04-08 | 2010-11-04 | 有限会社ミールジャパン | プロポリス組成物 |
| US20130142849A1 (en) * | 2010-08-17 | 2013-06-06 | Lupin Limited | Controlled release formulations of dronedarone |
| WO2016096999A1 (en) * | 2014-12-19 | 2016-06-23 | Synthon B.V. | Pharmaceutical composition comprising gefifinib |
| MX376083B (es) * | 2015-06-04 | 2025-03-07 | Pfizer | Formas de dosificacion solidas de palbociclib. |
| WO2017115746A1 (ja) * | 2015-12-28 | 2017-07-06 | 沢井製薬株式会社 | ゲフィチニブ含有錠剤 |
| US10449195B2 (en) | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
| WO2017223018A1 (en) * | 2016-06-23 | 2017-12-28 | Dow Global Technologies Llc | Esterified cellulose ethers comprising trimellityl groups |
| JP7198205B2 (ja) | 2017-07-11 | 2022-12-28 | クオリカプス株式会社 | 腸溶性硬質カプセル |
| BR112020026058A2 (pt) | 2018-06-22 | 2021-04-13 | Qualicaps Co., Ltd. | Cápsula entérica dura |
| CN114306245A (zh) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3608063A (en) * | 1969-08-15 | 1971-09-21 | Gilbert S Banker | Molecular drug entrapment process and compositions |
| US4178376A (en) * | 1977-01-21 | 1979-12-11 | Interx Research Corporation | Method for inducing rapid therapeutically effective antimalarial levels of certain selected conventional antimalarials |
| US4344934A (en) * | 1978-11-20 | 1982-08-17 | American Home Products Corporation | Therapeutic compositions with enhanced bioavailability |
| US4704284A (en) * | 1982-08-12 | 1987-11-03 | Pfizer Inc. | Long-acting matrix tablet formulations |
| US5342625A (en) * | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
| AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9207988D0 (en) * | 1992-04-10 | 1992-05-27 | Smithkline Beecham Plc | Topical composition |
| AU5171293A (en) * | 1992-10-14 | 1994-05-09 | Regents Of The University Of Colorado, The | Ion-pairing of drugs for improved efficacy and delivery |
| EP0716597A1 (en) * | 1993-08-30 | 1996-06-19 | Warner-Lambert Company | Tablet coating based on a melt-spun mixture of a saccharide and apolymer |
| US5559158A (en) * | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
| EP0682027B1 (de) * | 1994-05-03 | 1997-10-15 | Novartis AG | Pyrrolopyrimidinderivate mit antiproliferativer Wirkung |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| JP4713698B2 (ja) * | 1997-03-05 | 2011-06-29 | スージェン, インク. | 疎水性薬剤の処方 |
| ATE364374T1 (de) * | 1997-08-11 | 2007-07-15 | Pfizer Prod Inc | Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit |
| US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| DE19911509A1 (de) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6287599B1 (en) * | 2000-12-20 | 2001-09-11 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
| NZ527585A (en) * | 2001-02-15 | 2005-04-29 | Tanabe Seiyaku Co | Tablets quickly disintegrated in oral cavity |
| KR100397792B1 (ko) * | 2001-06-28 | 2003-09-13 | 한국과학기술연구원 | 4-(페닐아미노)-[1,4]디옥사노[2,3-g]퀴나졸린 유도체 및그의 제조방법 |
| GB0124455D0 (en) * | 2001-10-11 | 2001-12-05 | Pfizer Ltd | Pharmaceutical formulations |
| ES2342660T3 (es) * | 2002-02-26 | 2010-07-12 | Astrazeneca Ab | Nuevas formas cristalinas del compuesto anticancerigeno zd1839. |
| KR20100090726A (ko) * | 2002-02-26 | 2010-08-16 | 아스트라제네카 아베 | 수용성 셀룰로스 유도체를 포함하는 이레사의 약학 조제물 |
-
2003
- 2003-07-29 GB GBGB0317663.3A patent/GB0317663D0/en not_active Ceased
-
2004
- 2004-07-27 JP JP2006521656A patent/JP2007500176A/ja active Pending
- 2004-07-27 US US10/565,100 patent/US20070141141A1/en not_active Abandoned
- 2004-07-27 WO PCT/GB2004/003241 patent/WO2005011647A2/en not_active Ceased
- 2004-07-27 EP EP04743569A patent/EP1651233A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005011647A2 (en) | 2005-02-10 |
| US20070141141A1 (en) | 2007-06-21 |
| JP2007500176A (ja) | 2007-01-11 |
| EP1651233A2 (en) | 2006-05-03 |
| WO2005011647A3 (en) | 2005-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0320382D0 (en) | Pharmaceutical compositions | |
| GB0327723D0 (en) | Pharmaceutical compositions | |
| AU2003291103A8 (en) | Pharmaceutical composition | |
| GB0300427D0 (en) | Pharmaceutical composition | |
| IL164547A0 (en) | Pharmaceutical composition | |
| HU0301154D0 (en) | Pharmaceutical composition | |
| IL165878A0 (en) | Pharmaceutical composition | |
| GB0300531D0 (en) | Pharmaceutical compositions | |
| EP1648411A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| GB0307866D0 (en) | Pharmaceutical composition | |
| EP1699458A4 (en) | PHARMACEUTICAL COMPOSITION | |
| GB0329232D0 (en) | Pharmaceutical composition | |
| GB0317663D0 (en) | Pharmaceutical composition | |
| ZA200605080B (en) | Pharmaceutical compositions | |
| GB0300885D0 (en) | Pharmaceutical composition | |
| EP1600445A4 (en) | CURATIVE PREPARATION | |
| EP1655029A4 (en) | MEDICINAL COMPOSITIONS | |
| GB0306933D0 (en) | Pharmaceutical composition | |
| GB0307869D0 (en) | Pharmaceutical composition | |
| GB0305579D0 (en) | Pharmaceutical compositions | |
| GB0307864D0 (en) | Pharmaceutical composition | |
| GB0307867D0 (en) | Pharmaceutical composition | |
| GB0307862D0 (en) | Pharmaceutical composition | |
| GB0217703D0 (en) | Pharmaceutical composition | |
| GB0307865D0 (en) | Pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |